Bioshares Report and Recommendation

For those with access to the "Bioshares" publication, perhaps you can send a link to the full article.
I have received a copy and have cut and pasted the opening paragraph.... and the Summary.
Worth a read.... closing Recommendation has lifted from "Speculative Buy Class B... to Class A"

First para....
Viralytics (VLA: $1.025) is due to present data from clinical trials at the forthcoming AACR (American Association for Cancer Research) meeting in Washington DC on April 3 & 4 this year. Results from studies of Viralytics’ CAVATAK oncolytic cancer therapy will be discussed in two oral sessions and will be detailed in one poster session. These presentations can be regarded as high level......

...... Summary:-
Summary Release of new data at AACR will be a driver for increased interest in this stock, as will news of the company initiating additional Phase Ib studies or a decision to move into a pivotal study over the next 12 months.
Programs that may move into pivotal studies include the CAPRA, MITCI and Keynote-200 combination studies with Yervoy or Keytruda (in melanoma, NSCLC and metastatic bladder cancer). Other Phase Ib studies that the company may undertake include programs where Keytruda has approval, including head and neck cancer.
Viralytics is capitalised at $246 million. The company had $39.6 million in cash at the end of last year.
Bioshares recommendation: Speculative Buy Class A.